MDXG Stock Analysis: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$4.21
0.13 (3.06%)
▲
5d:
+0.12%
30d:
+13.96%
90d:
+7.27%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 29, 2026
14d
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MDXG shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: MDXG shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $4.21, which is considered extended relative to its 30-day fair value range of $3.65 to $4.04. The stock's valuation (Forward PE: 28.5) is in line with its historical norms (27.2). At these levels, the market is pricing in 1.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MDXG is in a downtrend. The price is approaching resistance at $4.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: MDXG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.60 (+61.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDXG is in a downtrend. The price is approaching resistance at $4.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: MDXG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.60 (+61.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.65 -
$4.04
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 61.8% below Wall St target ($6.60)
- NEUTRAL: Market pricing in 1.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$3.65 -
$4.04
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.72
Resistance Level
$4.30
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.47
Wall Street Target
$6.60
(+61.8%)
Revenue Growth (YoY)
-33.1%
Earnings Growth (YoY)
99.5%
Profit Margin
7.9%
Valuation Premium vs History
+1.6% premium
PE vs Historical
28.5 vs 27.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.6%
(market-implied from PE analysis)
1-Year Target
$4.15
(+2%)
2-Year Target
$4.21
(+3%)
3-Year Target
$4.28
(+5%)
3-Yr Target (if PE normalizes)
(PE: 28→27)
PE COMPRESSION
$4.09
(+0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 20.55 | Current EPS (TTM): $0.20
Bull Case
$3.24
(-21%)
Analyst growth -28.3%, PE expands to 22.6
Base Case
$2.94
(-28%)
Market implied -28.3%, PE stable at 20.6
Bear Case
$2.79
(-32%)
Severe decline -20.0%, PE contracts to 17.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 12:59 PM ET
Data refreshes hourly during market hours. Next update: 1:59 PM
Data refreshes hourly during market hours. Next update: 1:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
